Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective

被引：17

作者：

Altman R. ^{[1
]}

Vidal H.O. ^{[2
]}

机构：

[1] Centro de Trombosis de Buenos Aires, 1056 Buenos Aires

[2] Hospital Italiano de La Plata, Area de Hematología, Sección Hemostasia y Trombosis, Buenos Aires, 1900 La Plata, Pcia. de

来源：

Thrombosis Journal | / 9卷 / 1期

关键词：

Antiplatelet drugs; Apixaban; Aspirin; Atrial fibrillation; Dabigatran; Oral anticoagulants; Rivaroxaban;

D O I：

10.1186/1477-9560-9-12

中图分类号：

学科分类号：

摘要：

Warfarin has a long history of benefit and has become the gold standard medication for the prevention of ischemic stroke in patients with atrial fibrillation. Nevertheless, it is far from perfect and there is no doubt that new drugs must be found to replace warfarin. The new oral anticoagulants that are on the market or awaiting approval or under research offer some benefits but not enough to replace warfarin until results of additional studies can show an adequate balance between effectiveness/safety and cost/benefit. There are several issues concerning the new oral anticoagulants. It is essential that the effect of any anticoagulant can be measured in plasma. But to date, there is no test to assess the effect or therapeutic range for the new oral anticoagulants. There is no antidote to neutralize the action of the new drugs in cases of bleeding or when acute surgical intervention is necessary. Dabigatran requires dose adjustment in patients with moderate renal impairment and is contraindicated in patients with severe renal failure. Rivaroxaban should be used with caution in patients with severe renal impairment. Apixaban excretion is also partly dependent on renal function, although the impact of renal insufficiency has not yet been determined. How anticoagulant bridging can be done before surgery has not yet been established. In conclusion, although thousands of patients have been treated in phase III studies, additional data are necessary before conclusions can be drawn on the potential for these new anticoagulant drugs to replace warfarin in patients with atrial fibrillation. © 2011 Altman and Vidal; licensee BioMed Central Ltd.

引用

共 32 条

[1]

Shah S.V., Gage B.F., Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation, Circulation, 123, pp. 2562-2570, (2011)

[2]

Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., Singer D.E., Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study, JAMA, 285, pp. 2370-2375, (2001)

[3]

Waldo A.L., Becker R.C., Tapson V.F., Colgan K.J., Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation, J Am Coll Cardiol, 46, pp. 1729-1736, (2005)

[4]

Olesen J.B., Lip G.Y., Hansen M.L., Hansen P.R., Tolstrup J.S., Lindhardsen J., Selmer C., Ahlehoff O., Olsen A.M., Gislason G.H., Torp-Pedersen C., Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study, BMJ, 342, (2011)

[5]

Bavisotto L.M., Ellis D.J., Milner P.G., Combs D.L., Irwin I., Canafax D.M., Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants, J Clin Pharmacol, 51, pp. 561-574, (2011)

[6]

Bowersox S.S., Canafax D., Druzgala P., Milner P., Weitz J.I., Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models, Thromb Res, 126, (2010)

[7]

Ellis D.J., Usman M.H., Milner P.G., Canafax D.M., Ezekowitz M.D., The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation, Circulation, 120, pp. 1029-1035, (2009)

[8]

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials, Arch Intern Med, 154, pp. 1449-1457, (1994)

[9]

van Walraven C., Hart R.G., Singer D.E., Laupacis A., Connolly S., Petersen P., Koudstaal P.J., Chang Y., Hellemons B., Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis, JAMA, 288, pp. 2441-2448, (2002)

[10]

Hart R.G., Pearce L.A., Aguilar M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, pp. 857-867, (2007)

← 1 2 3 4 →